Person: ALİBAZ ÖNER, FATMA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ALİBAZ ÖNER
First Name
FATMA
Name
23 results
Search Results
Now showing 1 - 10 of 23
Publication Open Access Pulmonary artery wall thickness is increased in behcet's disease(2022-06-01) DİRESKENELİ, RAFİ HANER; ALİBAZ ÖNER, FATMA; Agackiran S. K. , Sunbul M., Kocakaya D., Kayaci S., DİRESKENELİ R. H. , Alibaz-Oner F.Publication Metadata only Kronik aerobik egzersizin takayasu arteritinde kardiyopulmoner sağlamlık ve vasküler fonksiyon üzerine olası koruyucu etkilerinin araştırılması(2022-05-12) ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; KASIMAY ÇAKIR, ÖZGÜR; Harman Yerli N., Abacar K., Alibaz Öner F., Direskeneli R. H., Kasımay Çakır Ö.Giriş: Takayasu arteriti (TA), büyük damarları etkileyen nadir bir vaskülittir.Amaç: Kronik aerobik egzersiz uygulamasının TA hastalığında olası koruyucu etkisininaraştırılması.Yöntem: Araştırmaya 20-55 yaş arasında 17 kadın TA hastası ve yaş ve Beden Kitle İndeksi(BKİ) eşleştirilmiş 11 kadın sağlıklı kontrol dahil edilmiştir (KON). TA hastaları; egzersizyapmayan grup (TAK, n=9) ve 12 hafta süreyle egzersiz yapan grup (TAK+Egz, n=8) olarakayrılmışlardır. Çalışma iki aşama olarak bazal ve deney sonu ölçümleri şeklindeplanlanmıştır; her iki aşamada da bütün katılımcılar antropometrik ölçümler, koşu bandıüzerinde kardiyopulmoner egzersiz testi (KPET), yakın kızılötesi spektroskopisi (NIRS)ölçümü, akım aracılı dilatasyon (FMD) ölçümleri, kan örnekleri, yaşam kalitesi anketi içinteste tabii tutulmuşlardır. Bazal ölçümleri alındıktan sonra TAK+Egz grubu 12 haftalıksüreçte haftada 3 gün ortayüksek şiddette zumba egzersizi yapmıştır. KON ve TAK grubuyapılandırılmış herhangi bir fiziksel aktiviteye katılmamışlardır.Bulgular: TAK ve TAK+Egz gruplarının maksimum oksijen tüketimi (VO2maks) ve%FMD’si bazal ölçümlerde kontrole göre daha düşüktü (p<0.05-0.01); TAK+Egz grubununVO2maks düzeyleri ve %FMD’si yükselmiştir (p<0.05). Anaerobik eşikteki oksijen tüketimi(VO2AT) TAK grubunda ilk ve son ölçümlerde KON grubundan daha düşüktü, TAK+Egzgrubunda ise egzersiz sonrasında bazale göre VO2AT değerleri yükselmiştir (p<0.05-0.01).İlk ölçümlerde TAK ve TAK+Egz grubunun maksimum kalp hızı (KHmaks) değerlerikontrolden daha düşükken egzersiz antrenmanıyla TAK+Egz grubunda ilk ölçüme kıyasla sonölçümde artmıştır (p<0.05). NIRS ölçümlerinde KON grubuna kıyasla TA gruplarında birfarklılık görülmezken, TAK+Egz grubunda egzersizle birlikte izometrik egzersizi sırasındaminimum % satürasyon ve derlenmede ortalama satürasyon artmıştır (p<0.05).Tartışma ve Sonuç: Çalışmamız egzersiz antrenmanının TA’de kardiyopulmoner sağlamlığıarttırdığını ve vasküler fonksiyonu iyileştirdiğini düşündürmektedir.Anahtar Sözcükler: Takayasu arteriti, egzersiz, endotelyal fonksiyon, VO2maks, anaerobikeşik.Publication Open Access Vascular Behcet's disease: a comparative study from Turkey and France(2022-08-01) ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; Alibaz-Oner F., Vautier M., Aksoy A., Mirouse A., Le Joncour A., Cacoub P., Ilgin C., Saadoun D., DİRESKENELİ R. H.Objective Vascular Behcet\"s disease (VBD) is a systemic vasculitis involving both arterial and venous vessels of all sizes and occurring in up to 40% of patients with BD. VBD is the main cause of mortality in BD. Although commonly seen around the Mediterranean region, comparative studies in VBD are lacking. We aimed to compare the course and therapeutic approaches of VBD in two large cohorts from Turkey and France. Methods We included 291 VBD patients (female/male:63/228, mean age: 41.2 +/- 11.3 years) who were followed up in the Department of Internal Medicine and Clinical Immunology at Pitie-Salpetriere Hospital, Sorbonne University, Paris, France (n=131) and Rheumatology Division of Marmara University School of Medicine, Istanbul, Turkey (n=160). All clinical and demographical data were acquired from patient charts retrospectively. Results Smoking, family history for BD, HLA-B*51 presence and pathergy positivity were significantly higher in Turkish patients (TR), while neurologic involvement was more prominent in the French (FR) group. After a median follow-up of 77 months, 562 vascular events occurred including 440 venous events, 115 arterial events and 7 cardiac thrombi. In 79 (29%) patients, first vascular event developed before BD diagnosis and for 77 (28%) of them, vascular involvement was the presenting sign of the disease. First relapse developed in 130 (44.7%) patients after median 24.5 (1-276) months of follow-up (TR: 46.3% (n=74), FR: 42.7% (n=56), p=0.56). Survival graph revealed that FR cohort has 1.64 times increased recurrent event risk compared to TR cohort (HR=1.64 (1.1-2.44), p=.014) and although did not reach to statistical significance, IS treatment after the first vascular event decreased further vascular events (HR= 0.66 (0.43-1.01, p=.057). Conclusion Almost half of patients relapsed of VBD within 2 years after the first vascular event. Immunosuppressants decrease VBD relapses.Publication Open Access C-reactive protein to albumin ratio is associated with disease activity in anti-neutrophil cytoplasmic antibody associated vasculitis(2023-01-01) ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; TUĞLULAR, ZÜBEYDE SERHAN; AŞICIOĞLU, EBRU; Atas D. B., Sahin G. K., ŞENGÜL Ş., KAYA B., PAYDAŞ S., ALİBAZ ÖNER F., DİRESKENELİ R. H., TUĞLULAR Z. S., AŞICIOĞLU E.Objective/Aim: C-reactive protein to albumin ratio (CAR) has recently been recognized as an independent prognostic marker for vasculitides. This study aims to investigate CAR and its relationship with disease activity and damage in prevalent ANCA associated vasculitis (AAV) patients. Methods: Fifty-one patients with AAV and 42 age-sex-matched healthy controls were enrolled in this crosssectional study. Birmingham vasculitis score (BVAS) was used to assess vasculitis activity and vasculitis damage index (VDI) to provide information on disease damage. Results: The median (25th-75th) age of the patients were 55 (48-61) years. CAR was significantly higher in AAV patients than controls (1.9±2.7 vs 0.7±0.4; p=0.006). The 75th percentile of BVAS was defined as high BVAS (BVAS≥5) and ROC curve analysis showed that CAR≥0.98 predicted BVAS≥5 with 70.0% sensitivity and 68.0% specificity (AUC:0.660, CI: 0.482-0.837, p=0.049). When patients with CAR≥0.98 were compared to those without, BVAS [5.0 (3.5-8.0) vs. 2.0 (0-3.25), p<0.001], BVAS≥5 [16 (64.0%) vs 4 (15.4%) patients, p:0.001], VDI [4.0 (2.0-4.0) vs. 2.0 (1.0-3.0), p=0.006], and CAR [1.32 (1.07-3.78) vs. 0.75 (0.60-0.83), p<0.001] were higher whereas albumin [3.8 (3.1-4.3) vs. 4.1 (3.9-4.4) g/dL, p=0.025] and haemoglobin [12.1 (10.4-13.4) vs. 13.0 (12.5-14.2) g/dL, p=0.008] were lower. Multivariate analysis revealed that BVAS [OR(95% CI):1.313 (1.003-1.719), p=0.047] was an independent factor associated with CAR≥0.98 in patients with AAV. Furthermore, correlation analysis showed that CAR significantly correlated with BVAS (r: 0.466, p=0.001). Conclusion: In this study, we observed that CAR was significantly associated with disease activity in AAV patients and can be used to monitor disease activityPublication Open Access Common femoral vein thickness measurement as a diagnostic test in incomplete behcet's disease(2022-06-01) ALİBAZ ÖNER, FATMA; ERGELEN, RABİA; ERGUN, SAFİYE ATLAS TÜLİN; DİRESKENELİ, RAFİ HANER; Alibaz-Oner F., Ergelen R., Temiz F., Agackiran S. K. , Soydemir E., Ergun T., DİRESKENELİ R. H.Publication Open Access Coronary arterial involvement can be observed in a significant subset of takayasu's arteritis patients by coronary ct-angiography(2022-06-01) ÇİNÇİN, AHMET ALTUĞ; BALTACIOĞLU, FEYYAZ; AKDENİZ DOĞAN, ZEYNEP DENİZ; DİRESKENELİ, RAFİ HANER; ALİBAZ ÖNER, FATMA; Abacar K., Cincin A., Baltacioglu F., AKDENİZ DOĞAN Z. D. , Sevik G., DİRESKENELİ R. H. , Alibaz-Oner. F.Publication Open Access Earlier and more aggressive treatment with biologics may prevent relapses and further new organ involvement in Behçet's disease(2023-03-01) BOZKURT, TUĞÇE; KARABACAK, MURAT; KUTLUĞ AĞAÇKIRAN, SEDA; DİRESKENELİ, RAFİ HANER; ALİBAZ ÖNER, FATMA; BOZKURT T., KARABACAK M., Karatas H., KUTLUĞ AĞAÇKIRAN S., Ergun T., DİRESKENELİ R. H., ALİBAZ ÖNER F.Objective: Immunosuppressives (IS) are the choice of treatment for major organ involvement in Behçet\"s disease (BD). In this study, we aimed to investigate the relapse rate and new major organ development in BD under ISs during long-term follow-up. Methods: The files of 1114 BD patients followed in Marmara University Behçet\"s Clinic were analyzed retrospectively. Patients with a follow-up less than 6 months were excluded. Conventional IS and biologic treatment courses were compared. ‘Events under IS’ were defined as a relapse of the same organ and/or new major organ development in patients receiving ISs. Results: Among 806 patients included in the final analysis (male: 56%, age at diagnosis: 29 (23–35) years, median follow-up time: 68 (33–106) months). Major organ involvement was present in 232 (50.5%) patients at diagnosis, and 227 (49.5%) developed new major organ involvement during follow-up. Major organ involvement developed earlier in males (p = 0.012) and in patients with a first-degree relative history of BD (p = 0.066). ISs were given mostly for major organ involvement (86.8%, n = 440). Overall, 36% of the patients had a relapse or new major organ involvement under ISs (relapse: 30.9%, new major organ involvement: 11.6%.) ‘Events under IS’ (35.5% vs 20.8%, p = 0.004), and relapses (29.3% vs 13.9%, p = 0.001) were more common with conventional ISs compared to biologics. Conclusion: Any major event under ISs was less common with biologics compared to conventional ISs in patients with BD. These results suggest that earlier and more aggressive treatment may be an option in BD patients who had the highest risk for severe disease course.Publication Open Access Prediction of subclinical left ventricular dysfunction by speckle-tracking echocardiography in patients with anti-neutrophil cytoplasmic antibody--associated vasculitis(2021-12-24) İZGİ, TUBA NUR; ATAŞ, HALİL; VELİOĞLU, ARZU; BARUTÇU ATAŞ, DİLEK; ILGIN, CAN; ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; ARIKAN, İZZET HAKKI; TUĞLULAR, ZÜBEYDE SERHAN; AŞICIOĞLU, EBRU; Izgi T. N., Atas D., ATAŞ H., Akaslan D., Ilgin C., VELİOĞLU A., ARIKAN İ. H., Alibaz-Oner F., DİRESKENELİ R. H., TUĞLULAR Z. S., et al.Objectives: This study aims to evaluate left ventricular functions using speckle-tracking echocardiography (STE) in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Patients and methods: Between June 2018 and July 2019, a total of 31 AAV patients (17 males, 14 females; median age: 53 years; range, 47 to 62 years) and 21 healthy controls (11 males, 10 females; median age: 56 years; range, 46 to 60 years) were included in the study. Clinical and biochemical characteristics of all participants were recorded. All participants underwent conventional and two-dimensional STE. The receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value of serum N-terminal prohormone of brain natriuretic peptide (NT-pro-BNP) that predicted subclinical left ventricular dysfunction. The Spearman correlation analysis was used to determine the correlation between left ventricular global longitudinal strain (LV-GLS) and NT-pro-BNP. Results: The LV-GLS was lower in AAV patients (19.3% vs. 21.7%, respectively; p=0.014). NT-pro-BNP was negatively correlated with LV-GLS (p=0.005, r=0.401). Conclusion: Subclinical left ventricular dysfunction can be detected by STE in patients with AAV who have free of clinically overt cardiovascular disease. The LV-GLS is negatively correlated with serum NT-pro-BNP levels.Publication Metadata only Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus(2022-05-01) YILMAZ, YUSUF; BARUTÇU ATAŞ, DİLEK; ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; TUĞLULAR, ZÜBEYDE SERHAN; AŞICIOĞLU, EBRU; VELİOĞLU, ARZU; Yetginoglu O., Atas D., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., Direskeneli H., Tuglular S., Asicioglu E.Objective Although liver dysfunction is not considered the main organ involvement in Systemic Lupus Erythematosus (SLE), the frequency of liver dysfunction or abnormal liver enzyme values may be observed in 50-60% of patients. The aim of this study was to assess fatty liver and liver fibrosis in SLE patients using Fibroscan as well as determine associated factors such as immunosuppressive medications. Methods Sixty SLE patients and 30 healthy controls were included. Patients with HBV, HCV or cirrhosis, malignancy, cardiac disease, or patients on dialysis were excluded. All participants underwent Fibroscan measurements. Results The prevalence of fatty liver disease was similar between SLE patients and healthy controls (21.7 vs 26.7%, p = .597). Liver fibrosis was also similar between the two groups (26.7 vs 10.0%, p = .069). Since the majority of SLE patients were female, we performed a subgroup analysis in female patients (n = 51) and controls (n = 25). Fatty liver disease was similar between female SLE patients and controls (23.5 vs 24.0%, p = .964). However, liver fibrosis in female patients with SLE was increased compared to female controls (29.4 vs 4.0%, p = .011) and was associated with age (Exp (B) 95% CI: 1.083 (1.006-1.166), p = .034) and low-dose cumulative glucocorticoid use (Exp (B) 95% CI: 14.116 (1.213-164.210), p = .034). Conclusion The prevalence of fatty liver was similar between SLE patients and controls, while liver fibrosis was increased in the female patient group as compared to controls. Furthermore, liver fibrosis was associated with age and low dose cumulative glucocorticoid use. Interestingly, fatty liver did not precede liver fibrosis in the majority of cases, contrary to what is observed in the general population. Larger studies are needed to confirm our findings and determine whether immunosuppressive use has any impact on the development of liver fibrosis in SLE patients.Publication Open Access Earlier and more aggressive treatment of major organ involvement with biologics may prevent relapses or further new organ involvement in a subgroup of behcet's disease patients(2022-06-01) ERGUN, SAFİYE ATLAS TÜLİN; DİRESKENELİ, RAFİ HANER; ALİBAZ ÖNER, FATMA; Bozkurt T., Karabacak M., Karatas H., Agackiran S. K. , Ergun T., DİRESKENELİ R. H. , Alibaz-Oner F.
- «
- 1 (current)
- 2
- 3
- »